[Reduction of cardiovascular events with lorsartan? The LIFE Study].
Medizinische Klinik II, Universitätsklinikum Lübeck. heribert.schunkert@innere2.uni-luebeck.de
H
H
Schunkert
D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000401:mortality / Q000517:prevention & control*; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D019808:Losartan / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control*; D044140:Receptor, Angiotensin, Type 1; D015996:Survival Rate; D016896:Treatment Outcome
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D044140:Receptor, Angiotensin, Type 1; D001262:Atenolol; D019808:Losartan